Malignant Ascites Clinical Trial
Official title:
Phase I-II Clinical Study of PRaG（PD-1 Inhibitor Intravenous Injectio,Radiotherapy and GM-CSF）Combined With PD-1 Inhibitor Intraperitoneal Perfusion for Advanced Refractory Solid Tumors Combined With Malignant Ascites
The effect and safety of intraperitoneal infusion of PD-1 inhibitor is unclear for patients with peritoneal metastasis of advanced malignant tumors and malignant ascites. It is planned to determine the safety and efficacy of intraperitoneal infusion of PD-1 inhibitor combination with PRaG therapy.
Patinets with peritoneal metastasis have limited treatment and poor prognosis. Evidence has shown that there are T lymphocates and macrophages in the ascites microenviroment.We suggested the Intraperitoneal infusion of PD-1 inhibitor might activate T cells and produce anti-tumor effect.The intraperitoneal infusion of PD-1 inhibitorand combined with PRaG(Intravenous injectionof PD-1 inhibitor, Radiotherapy and GM-CSF）might benefit the survival of patients with peritoneal metastasis of advanced malignant tumors with malignant ascites. It is planned to determine the safety in phase I clinical trial. Further through phase II clinical trials, to clarify the effectiveness of this therapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06200376 -
A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT04051112 -
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites
|
Phase 1 | |
| Completed |
NCT00836654 -
Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT03550560 -
EUS-Guided Drainage of Refractory Malignant Ascites
|
||
| Recruiting |
NCT04501744 -
A Study of M701 (EpCAM and CD3) in Malignant Ascites
|
Phase 1 | |
| Terminated |
NCT00028782 -
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
|
N/A | |
| Recruiting |
NCT05477927 -
Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases
|
Phase 1 | |
| Active, not recruiting |
NCT06266091 -
Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody
|
Phase 2 | |
| Withdrawn |
NCT04076566 -
Malignant Ascites Alfapump® Study
|
||
| Enrolling by invitation |
NCT01854866 -
Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion
|
Phase 2 | |
| Recruiting |
NCT03230708 -
Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites
|
Phase 1/Phase 2 | |
| Completed |
NCT01327235 -
Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
|
Phase 2 | |
| Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
| Terminated |
NCT02496286 -
Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites
|
Phase 1 | |
| Completed |
NCT01532427 -
ALFApump System Post Marketing Surveillance Registry
|
||
| Completed |
NCT00326885 -
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
|
Phase 2 | |
| Recruiting |
NCT02530398 -
A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites
|
Phase 1 | |
| Withdrawn |
NCT00908219 -
A Study of Bevacizumab to Prevent Malignant Ascites
|
Phase 2 | |
| Recruiting |
NCT06016179 -
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT03736122 -
A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites
|
Phase 1/Phase 2 |